

REMARKS

Claim 17 is amended.

Claim 18 is new.

Claims 10-15 are canceled without prejudice.
Applicants reserve the right to pursue this subject matter in one or more divisional applications.

Claims 16-18 remain pending.

Responsive to the restriction requirement imposed in the outstanding Official Action, applicants elect Group II, claims 16-18 drawn to a method of treating mutant P53 mediated disease, without traverse.

Responsive to the election of species requirement, applicants elect a methylene group linked to a nitrogen atom contained in the ring structure of a purine for R1 and an oxygen atom being doubled bonded for A, without traverse.

A favorable action on the merits of the pending claims is accordingly respectfully requested.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any

overpayment to Deposit Account No. 25-0120 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17.

Respectfully submitted,

YOUNG & THOMPSON



Robert Madsen, Reg. No. 58,543
745 South 23rd Street
Arlington, VA 22202
Telephone (703) 521-2297

RAM/fb